Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52 GBX | 0.00% | 0.00% | +0.97% |
04-23 | Cambridge Cognition partly-owned spin-off gets GBP1.5 million funding | AN |
04-23 | Cambridge Cognition's Spin-Out Company Closes Fundraise for Schizophrenia Drug | MT |
Sales 2023 * | 13.5M 16.86M 23.05M | Sales 2024 * | 16M 19.99M 27.32M | Capitalization | 16.17M 20.2M 27.61M |
---|---|---|---|---|---|
Net income 2023 * | -3M -3.75M -5.12M | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 1.18 x |
Net cash position 2023 * | 200K 250K 342K | Net cash position 2024 * | 150K 187K 256K | EV / Sales 2024 * | 1 x |
P/E ratio 2023 * |
-5.15
x | P/E ratio 2024 * |
-37.4
x | Employees | 80 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 71.79% |
Current month | -7.47% | ||
1 month | -6.31% | ||
3 months | +5.05% | ||
6 months | -25.71% | ||
Current year | +0.97% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Stork
CEO | Chief Executive Officer | 55 | 19-03-11 |
Stephen Symonds
DFI | Director of Finance/CFO | 50 | 22-04-05 |
Steven Powell
CHM | Chairman | 63 | 15-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Bungay
BRD | Director/Board Member | 55 | 20-09-13 |
Stuart Gall
BRD | Director/Board Member | 62 | 01-31 |
Steven Powell
CHM | Chairman | 63 | 15-07-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 52 | 0.00% | 4,800 |
24-04-25 | 52 | 0.00% | 3,759 |
24-04-24 | 52 | 0.00% | 30,351 |
24-04-23 | 52 | 0.00% | 49,034 |
24-04-22 | 52 | 0.00% | 0 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.97% | 20.14M | |
-20.09% | 26.53B | |
+1.38% | 9.32B | |
-25.68% | 729M | |
-1.92% | 479M | |
-9.71% | 448M | |
-9.63% | 273M | |
-28.88% | 210M | |
-42.63% | 189M | |
-6.34% | 152M |
- Stock Market
- Equities
- COG Stock